Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31698371 | 0.76 | EPRS1 (0.32) | EPRS1 | |
| SCHEMBL31698039 | 0.72 | ESR1 (0.40) | MAP3K12 | |
| SCHEMBL31698452 | 0.69 | AR (0.41) | ARCFTR | |
| SCHEMBL25340301 | 0.69 | ROCK1 (0.34) | AR | |
| SCHEMBL31349498 | 0.68 | AR (0.36) | AR | |
| SCHEMBL25930458 | 0.68 | NPC1 (0.36) | AREPRS1 | |
| SCHEMBL20488090 | 0.66 | EPRS1 (0.35) | EPRS1 | |
| SCHEMBL20488486 | 0.66 | EPRS1 (0.37) | AREPRS1 | |
| SCHEMBL28880706 | 0.65 | HDAC6 (0.35) | AREPRS1 | |
| SCHEMBL31349612 | 0.65 | AR (0.33) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | AR 2954/4885PGR 3715/4885LRRK2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.